Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lyra Therapeutics (LYRA) EPS (Basic) (2021 - 2025)

Historic EPS (Basic) for Lyra Therapeutics (LYRA) over the last 5 years, with Q3 2025 value amounting to -$3.38.

  • Lyra Therapeutics' EPS (Basic) rose 6273.43% to -$3.38 in Q3 2025 from the same period last year, while for Sep 2025 it was $53.0, marking a year-over-year increase of 21422.41%. This contributed to the annual value of -$1.43 for FY2024, which is 1401.81% down from last year.
  • Per Lyra Therapeutics' latest filing, its EPS (Basic) stood at -$3.38 for Q3 2025, which was up 6273.43% from -$5.51 recorded in Q2 2025.
  • Lyra Therapeutics' 5-year EPS (Basic) high stood at -$0.13 for Q1 2025, and its period low was -$36.76 during Q2 2024.
  • Over the past 5 years, Lyra Therapeutics' median EPS (Basic) value was -$0.47 (recorded in 2022), while the average stood at -$3.28.
  • Per our database at Business Quant, Lyra Therapeutics' EPS (Basic) tumbled by 1011111.11% in 2024 and then soared by 8501.09% in 2025.
  • Lyra Therapeutics' EPS (Basic) (Quarter) stood at -$1.05 in 2021, then soared by 55.14% to -$0.47 in 2022, then surged by 35.3% to -$0.3 in 2023, then soared by 44.59% to -$0.17 in 2024, then tumbled by 1904.6% to -$3.38 in 2025.
  • Its last three reported values are -$3.38 in Q3 2025, -$5.51 for Q2 2025, and -$0.13 during Q1 2025.